Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
2024

Shifting the Paradigm of Type 1 Diabetes: A Narrative Review of Disease-Modifying Therapies

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): O’Donovan Alexander J., Gorelik Seth, Nally Laura M.

Primary Institution: Yale University School of Medicine

Hypothesis

Advancements in therapies that can delay the onset of clinical type 1 diabetes are crucial.

Conclusion

The review highlights the potential of various disease-modifying therapies to delay the progression of type 1 diabetes.

Supporting Evidence

  • Teplizumab is the first drug approved by the FDA to delay the progression from stage 2 to stage 3 type 1 diabetes.
  • Studies show that teplizumab can preserve beta cell function and reduce insulin requirements in patients with type 1 diabetes.
  • Various therapies are being studied to intervene at different stages of type 1 diabetes to improve health outcomes.

Takeaway

This study looks at new treatments that can help kids with type 1 diabetes not get sick as fast. It's like finding ways to keep them healthy for longer.

Methodology

A comprehensive literature review was conducted using PubMed and ClinicalTrials.gov to identify published trials and ongoing research on disease-modifying therapies in type 1 diabetes.

Limitations

The review may not cover all ongoing studies due to the rapidly evolving nature of research in this field.

Digital Object Identifier (DOI)

10.3389/fendo.2024.1477101

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication